While the U.S. government was initially the exclusive purchaser and distributer of COVID-19 vaccines and therapeutics, COVID-19 medical countermeasures will increasingly shift to being provided by commercial markets and accessible to people through traditional pathways. COVID-19 vaccines and therapeutics are the first products to make this transition but may not be the last. This page provides resources on the shift of products from government purchasing and distribution to commercial channels.
The resources in this Topic Collection highlight these considerations, factors, and research from a variety of sources to provide guidance for stakeholders who are interested in the commercialization of vaccines, therapeutics, and other products developed with the support of the U.S. government and later transitioned to commercial channels.